Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Recruiting Phase 4 Interventional

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

NCT06714864
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
(taurolidine and heparin) catheter lock solution, Standard of Care
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 10:00 AM EDT
Not listed Phase 2Phase 3 Interventional

Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration

NCT02127463
View directory record Official record
Conditions
Non-Exudative Age Related Macular Degeneration
Interventions
MC-1101, MC-1101 Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 28, 2026, 10:00 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 28, 2026, 10:00 AM EDT
Recruiting Not applicable Interventional

Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT)

NCT06736444
View directory record Official record
Conditions
Insomnia, Alcohol Use, Marijuana Use
Interventions
Brief Behavioral Therapy for Insomnia (BBTI), Brief Alcohol Screening and Intervention for College Students (BASICS), Attention Control
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 29 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

NCT03854344
View directory record Official record
Conditions
Pain, Postoperative, Burns
Interventions
Lidocaine Hydrochloride, Liposomal bupivacaine, Bupivacaine Hydrochloride
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

NCT01968187
View directory record Official record
Conditions
Hyperphagia in Prader-Willi Syndrome
Interventions
FE 992097, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
10 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Gainesville, Florida • Mineola, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 28, 2026, 10:00 AM EDT
Not listed Not applicable Interventional

Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning

NCT06418022
View directory record Official record
Conditions
Shock, Fluid Overload, Cardiac Output, Low
Interventions
Trendelenburg positioning VTI
Device
Lead sponsor
Lenox Hill Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

NCT03479307
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Phoenix, Arizona • Torrance, California • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 28, 2026, 10:00 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

NCT01732211
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
PD 0360324, Normal Saline for injection
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 4 Interventional Results available

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507
View directory record Official record
Conditions
Weight Gain
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 28, 2026, 10:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Retinal Imaging

NCT01866371
View directory record Official record
Conditions
Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy
Interventions
Retinal imaging
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 10:00 AM EDT
Terminated Not applicable Interventional

Rapid Pleurodesis Through an Indwelling Pleural Catheter

NCT03325192
View directory record Official record
Conditions
Pleural Effusion, Malignant, Pleurodesis, Pleural Diseases
Interventions
Rapid pleurodesis protocol, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

NCT05736107
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 28, 2026, 10:00 AM EDT
Terminated Phase 3 Interventional

Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease

NCT00930436
View directory record Official record
Conditions
Contrast Induced Kidney Injury.
Interventions
sodium bicarbonate
Drug
Lead sponsor
MD Scientific
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Rome, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery

NCT01783236
View directory record Official record
Conditions
Lung Tumor
Interventions
IV Acetaminophen, Saline Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01270971
View directory record Official record
Conditions
Onychomycosis of Toenails
Interventions
AN2690 Topical Solution, 5%, Solution Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Burbank, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Not applicable Interventional

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

NCT02591355
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Autologous Platelet Rich Plasma, Saline solution injection
Device
Lead sponsor
Regen Lab SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 28, 2026, 10:00 AM EDT
Recruiting Phase 2 Interventional

HPV Vaccine, Imiquimod, and Metformin Combination Trial

NCT06686043
View directory record Official record
Conditions
Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Interventions
HPV vaccine, Imiquimod, and metformin combination therapy
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 2 Interventional

Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS

NCT00579085
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
Ketamine, IV NSS, Normal Saline
Drug · Other
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 28, 2026, 10:00 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

NCT07498426
View directory record Official record
Conditions
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Interventions
NIO752, Placebo
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
41 Years to 81 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

NCT03660878
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 28, 2026, 10:00 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

NCT07205900
View directory record Official record
Conditions
Obese, Obesity
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Oak Lawn, Illinois • Ames, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 28, 2026, 10:00 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

NCT03502707
View directory record Official record
Conditions
Healthy
Interventions
Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
669 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 28, 2026, 10:00 AM EDT